Comparison of the EORTC QLQ-EN24, FACT-En, and FEnSI-23 for assessing quality of life in endometrial cancer: a systematic review.

Curr Opin Support Palliat CareMay 28, 2026 (epub)
Clinical ResearchOncology (Medical)Obstetrics & Gynecology

Tiffany Zhang, Shely Kagan, Andrew Bottomley et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review compares three patient-reported outcome measures for assessing quality of life in endometrial cancer: EORTC QLQ-EN24, FACT-En, and FEnSI-23. Each measure has distinct strengths, with EORTC QLQ-EN24 excelling in symptom assessment, FACT-En in broader quality of life evaluation, and FEnSI-23 focusing on patient-centered disease symptoms. The review emphasizes the need for further validation across diverse populations.

Key findings

  • EORTC QLQ-EN24 is validated in multinational settings and excels in treatment-induced symptom assessment.
  • FACT-En provides a comprehensive evaluation of physical, emotional, social, and functional well-being.
  • FEnSI-23 emphasizes disease-related symptoms and treatment side effects, incorporating patient perspectives.

Why it matters

Understanding the strengths and limitations of these quality of life measures is essential for clinicians to select appropriate tools for assessing patient experiences and outcomes in endometrial cancer care.

Source

PubMed · PMID 42213858

Published in Curr Opin Support Palliat Care. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.